The FIP CEO Interviews... Trevor Jones
A webinar organised by: FIP CEO interviews . . .
23 June 2020
Prof. Trevor Jones, Professor, King's College London, Former Head of R&D, Wellcome UK
A visiting professor at King's College London, and a former Head of R&D, at Wellcome. He continues to have a distinguished career in the pharmaceutical and biotech industry as well as in academia.
He was main board director for Research & Development at The Wellcome Foundation Ltd (Wellcome plc). During his tenure, the organisation was responsible for the development of a number of significant products. He was not only involved in the introduction of the HIV/AIDS drug AZT at his time with the Wellcome Foundation but also its pricing in the USA/EU and liaison with the South African Government over patents.
Prof. Jones assisted the Government to attract inward investment into the UK, particularly from the Japanese pharmaceutical companies through the "Prescribe UK" initiative (with Virginia Bottomley and David Sainsbury). He also led negotiations with the UK Government on the Pharmaceutical Price Regulation Scheme (PPRS) when he was head of the ABPI. His latest role is advising the Wales Government on the future of the NHS as a member of The Bevan Commission. He is also a non-executive director of the new life science investment fund, Arix Bioscience Plc and the Oxford based Drug Discovery company, e-Therapeutics plc.
Prof. Jones is a member on the FIP Expert Advisory Group for COVID-19 and has always been an active member in FIP:
Member of the Board of Pharmaceutical Science of FIP - 1980-1984
Member of Industrial Pharmacy Committee 1978-1983
Member of FIP expert working group on drug dissolution 1979-1984
President of the FIP International Commission of Technology 1979-1983